Completed
A 3-Month Open-Label Safety and Efficacy Study of TNX-102 SL Tablets in Fibromyalgia Patients
NCT02589275
- Conditions
- Fibromyalgia, Muscular Diseases, Musculoskeletal Diseases, +4 more
- Locations
-
- Birmingham, Alabama, United States
- Phoenix, Arizona, United States
- Sacramento, California, United States
- San Diego, California, United States